• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.

作者信息

Maechler Melanie, Bacher Ulrike, Daskalakis Michael, Nilius Henning, Nagler Michael, Taleghani Behrouz Mansouri, Jeker Barbara, Pabst Thomas

机构信息

Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland.

Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern, Switzerland.

出版信息

Hematol Oncol. 2023 Aug;41(3):583-586. doi: 10.1002/hon.3055. Epub 2022 Aug 6.

DOI:10.1002/hon.3055
PMID:35920140
Abstract
摘要

相似文献

1
Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.干细胞释放化合物普乐沙福用于骨髓瘤患者外周血干细胞采集的长期安全性。
Hematol Oncol. 2023 Aug;41(3):583-586. doi: 10.1002/hon.3055. Epub 2022 Aug 6.
2
Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.使用普乐沙福在镰状细胞病患者中进行安全有效的外周血干细胞采集。
Haematologica. 2020 Oct 1;105(10):e497. doi: 10.3324/haematol.2019.236182.
3
Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.低 CD34 血细胞计数患者挽救性化疗后自体造血外周血干细胞的成功动员。
Transplant Cell Ther. 2022 Nov;28(11):754-759. doi: 10.1016/j.jtct.2022.08.017. Epub 2022 Aug 22.
4
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.在恶性淋巴瘤或多发性骨髓瘤患者中，在使用粒细胞集落刺激因子的基础上加用普乐沙福用于造血干细胞动员以进行自体移植。
Cochrane Database Syst Rev. 2015 Oct 20;2015(10):CD010615. doi: 10.1002/14651858.CD010615.pub2.
5
Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.在培瑞克昔福 era 开发外周血造血干细胞采集产量的定量预测模型。
Cytotherapy. 2022 Jan;24(1):49-58. doi: 10.1016/j.jcyt.2021.09.004. Epub 2021 Oct 12.
6
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞：一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.
7
Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.我们是否明智地选择了多发性骨髓瘤自体干细胞移植的动员方案：GCSF+/-plerixafor 与环磷酰胺/GCSF+/-plerixafor 的单中心比较。
J Clin Apher. 2022 Aug;37(4):348-353. doi: 10.1002/jca.21976. Epub 2022 Feb 26.
8
Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study.培洛昔福在自体移植前动员外周血造血干细胞的益处：一项双中心回顾性队列研究。
Cytotherapy. 2023 Jul;25(7):773-781. doi: 10.1016/j.jcyt.2023.02.006. Epub 2023 Mar 12.
9
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.培洛昔福联合粒细胞集落刺激因子在淋巴瘤和多发性骨髓瘤一线稳定期自体外周血造血干细胞动员中的应用：前瞻性 PREDICT 试验结果。
Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.
10
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.在新诊断的多发性骨髓瘤中，用包含达雷妥尤单抗和来那度胺的四联诱导治疗进行干细胞动员的结果：来自 MASTER 和 GRIFFIN 试验的结果。
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.

引用本文的文献

1
CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment.CXCR家族与骨髓微环境中的血液系统恶性肿瘤
Biomolecules. 2025 May 13;15(5):716. doi: 10.3390/biom15050716.
2
Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial.骨髓瘤患者干细胞动员采用化疗联合细胞因子（粒细胞集落刺激因子）与单纯使用细胞因子的比较研究（MOCCCA）：一项随机II期、开放标签、非劣效性试验
Bone Marrow Transplant. 2025 Mar;60(3):270-276. doi: 10.1038/s41409-024-02468-z. Epub 2024 Nov 15.
3
Rising Prevalence of Low-Frequency Gene Mutations after Second HDCT in Multiple Myeloma.
多发性骨髓瘤患者接受第二次大剂量化疗后低频基因突变的患病率上升
Curr Issues Mol Biol. 2024 Jul 29;46(8):8197-8208. doi: 10.3390/cimb46080484.
4
Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma.伊沙佐米与粒细胞集落刺激因子联合用于多发性骨髓瘤患者的干细胞动员
Cancers (Basel). 2023 Jan 9;15(2):430. doi: 10.3390/cancers15020430.